The gene encoding the opioid receptor, OPRM1, contains at least two polymorphisms affecting protein sequence in exon 1, Ala6Val and Asp40Asn. In previous studies, each variant has been reported to be associated with some form of drug dependence. Although past reports have not been consistent, they have also not considered comparable populations. The goals of the present study were to delineate allele and haplotype frequencies of these variants in a range of populations, and in drug-or alcohol-dependent subjects deriving from some of those populations. We developed new PCR-RFLP methods to detect both of these polymorphisms and studied them in control and substance-dependent populations of African American (AA), European American (EA) and Hispanic origin, and in a series of populations differing in geographic origin (Japanese, Ethiopians, Bedouins, and Ashkenazi Jews), 891 subjects overall. We designed primers flanking the DNA segment containing both polymorphisms, each primer creating a different artificial restriction site, such that a single PCR reaction can be completed, then divided, and the PCR product digested with either of two enzymes to reveal both polymorphisms. We found that allele frequencies for both polymorphic systems were significantly different between AA and EA subjects, and there was significant heterogeneity among the more extensive set of populations. Furthermore, there were no significant differences in allele frequency by diagnosis; that is, neither polymorphism appears to be a direct risk factor for substance dependence. Finally, we demonstrated linkage disequilibrium between the two exon 1 markers, and a previously described short tandem repeat (STR) marker.
Introduction
The opioid receptor plays a central role in mediating the effects of morphine and related opioid agonists. 1 The OPRM1 gene encodes the opioid receptor, OPRM1 maps to chromosome 6q24-q25. 2 Targeted disruption of the homologous gene in mice abolishes morphine-induced analgesia, place-preference activity, and morphine-induced physical dependence in null homozygotes. 3, 4 Naltrexone, an approved pharmacological treatment for alcohol dependence, 5, 6 acts as an antagonist of the three opioid receptor types; this medication was first developed for the treatment of opiate dependence, based on its opiate antagonist activity. A QTL mapping study 7 was consistent with polymorphic variation at the opioid receptor locus in mouse affecting morphine preference.
A growing body of data supports a role for the endogenous opioid system in the reinforcing effects of a variety of drugs that are self-administered by animals and abused by humans, including nicotine, cocaine, amphetamines, alcohol, and cannabinoids. All of these drugs (as well as opioids) have been shown to release dopamine in the nucleus accumbens (NAc), 8, 9 which is thought to provide a common pathway for reinforcement. 10 In turn, opioid receptors in the ventral tegmental area (VTA) are involved in the modulation of NAc dopaminergic activity. For example, infusion of a receptor agonist into the VTA increases dopamine release into the NAc, while infusion of a receptor antagonist decreases dopamine release. 11 Furthermore, alcohol preferring (AA) rats show a significantly higher density of opioid receptors in the VTA (and related limbic brain regions), in comparison to alcohol avoiding (ANA) rats. 12 Therefore, genetic variation at loci coding for opiatesystem proteins, including OPRM1, might be expected to affect risk for drug dependence and alcoholism, and possibly other addictive behaviors as well.
Four recent studies examined the association between OPRM1 alleles and alcohol and/or drug dependence. Berrettini et al 13 identified two polymorphisms of OPRM1, one in a non-coding region and the second producing a change in the predicted protein sequence (Ala6Val). They compared the frequency of the variant alleles in a sample of 55 substance-dependent subjects (53% European American (EA), 47% African American (AA)) with a group of 51 controls (43% EA, 57% AA).) The substance-dependent group had a higher frequency of the Ala6Val variant (f = 0.22) than controls (f = 0.10) that was marginally significant (P = 0.05). However, allele frequencies were not significantly different between EA and AA subjects in this sample, and observations for EA and AA subjects were combined.
Bergen et al 14 directly sequenced 91% of the OPRM1 coding sequence (1093 basepairs) and 1479 bases of intronic and untranslated sequence. They found four DNA sequence variants, including three that change protein sequence (Ala6Val, as reported by Berrettini et al; 13 also, Asn40Asp and Ser147Cys) and one intronic variant (IVS2 + 691G/C). The variant forms of the exonic polymorphisms other than Asn40Asp were rare in the populations studied, in contrast to the report by Berrettini et al 13 for Ala6Val. Using OPRM1 genotypes and haplotypes from US Caucasian, Finnish Caucasian and Southwestern American Indian samples, these investigators conducted association and sib-pair linkage analyses with diagnoses of alcohol dependence and drug dependence. No significant associations were observed. Bond et al 15 described functional variation corresponding to Asn40Asp (A118G); the differing forms vary in their sensitivity to ␤-endorphin (but not to other possible endogenous and exogenous ligands, including met-enkephalin, dynorphin A, morphine, and methadone; or to naloxone). The observed difference corresponded to about a three-fold alteration in affinity. These authors also described a statistically significant association of that variant with opioid dependence, but only in Hispanic subjects. In that population, frequency of the less common (Asp or G) allele was 0.10 in 58 opioid-dependent subjects, but 0.39 in nine non-dependent controls. Allele frequencies differed significantly by population in this sample as well. When they combined subjects from different populations (despite the observed difference in allele frequency by population), they also observed a significant difference in allele frequency at the Ala6Val system between opioid-dependent subjects and controls.
We have previously reported a possible association of an STR polymorphism at this locus to substance dependence 16 and described its basic population genetics. 17 The reports by Berrettini et al, 13 Bergen et al, 14 and Bond et al 15 raise important possibilities regarding potential effects of OPRM1 exon 1 variants on risk for substance dependence and on function of the opioid receptor protein, but these reports are inconsistent. As discussed above, Berrettini et al 13 reported an association of Ala6Val with substance dependence, but also pooled EA and AA samples; they found no difference in allele frequencies between these populations. In order to address a possible relationship of polymorphic variation at this locus to alcohol and/or drug dependence, and to delineate the basic population genetics of these polymorphic systems, we studied both exon 1 polymorphisms in a total of 891 subjects: control populations of varying geographic origin (United States: EA, AA, and Hispanic; and Ethiopian Jews, Ashkenazi Jews, Bedouins, and Japanese) and varying diagnoses (EA, AA, and Hispanic drug-dependent subjects; EA alcohol-dependent subjects). We developed rapid PCR-RFLP assays for both polymorphisms, designing primers creating artificial restriction sites including both polymorphic bases. Genotyping both polymorphisms from the same PCR product also allowed molecular haplotyping in the few subjects heterozygous at both systems. We then addressed linkage disequilibrium (LD) relationships between the STR and the exon 1 polymorphisms.
Materials and methods

Clinical
American control subjects: EA, AA, and Hispanic control subjects (see Table 1 for sample sizes) were collected at the VA CT Healthcare System, West Haven Campus, and at the University of Connecticut. The majority of these subjects were screened to exclude major psychiatric diagnoses, as described elsewhere. 18 Substance dependent (ie, alcohol-dependent and drugdependent) subjects All subjects (see Table 1 ) were recruited at the University of Connecticut (CT) School of Medicine (Farmington) or VA CT Healthcare System (West Haven). All substance-dependent subjects were diagnosed using DSM-III-R criteria. 19 The diagnosis was made with the Structured Clinical Interview for DSM-III-R (SCID), 20 the computerized Diagnostic Interview Schedule for DSM-III-R (C-DIS-R), 21 or a checklist comprised of DSM-III-R symptoms.
Other populations DNA from unrelated Ashkenazi Jews, Ethiopian Jews, and Bedouins was obtained from the National Laboratory for the Genetics of Israeli Populations, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel. Samples from unrelated Japanese subjects were provided by Drs H Ichinose and T Nagatsu, as described previously.
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Regression analysis A total of 519 subjects were included in the analysis that examined the relationship between OPRM1 genotypes and substance dependence by logistic regression.
(Unscreened (random population) control subjects were included in allele frequency comparisons by diagnosis, but excluded from regression analysis.) Of this number, 77.6% were dependent on one or more of the following substances: alcohol (n = 316), cocaine (n = 202), or opioids (n = 79). The remaining subjects (n = 116) were without a major psychiatric disorder based on administration of the SCID (n = 84) or an unstructured clinical interview (n = 32). The majority (71.2%) of substance-dependent subjects were male. The mean age of this group was 37.9 (SD = 9.4) years. The racial/ethnic breakdown of the group was: 80.6% EA, 18.9% AA, and 6.9% Hispanic. The control group was 54.3% male, with a mean age of 31.8 (SD = 10.6) years. The racial/ethnic breakdown of the group was 62.1% EA, 29.3% AA, and 8.6% Hispanic. Laboratory PCR primers, designed based on reported sequence 14 and incorporating mismatched bases (capitalized below) to produce artificial restriction sites (bold), were ArtUp (5Ј-ccg tca gta cca tgg aca gca gcg Gtg-3Ј) and R2-D2 (5Ј-gtt cgg acc gca tgg gtc gga cag AT-3Ј), yielding a 154-bp PCR product. PCR cycling parameters consisted of a 5-min hold at 95°C, followed by 30 cycles of 95°C (30 s) and 72°C (60 s). From the 15-l reaction mixture, 5 l was digested in 10 u BanI (New England Biolabs, Beverly, MA, USA; recognition sequence, 5Ј-GG [C or T][G or A]CC-3Ј), and 5 l digested in 10 u DpnII (NEB; recognition sequence, 5Ј-GATC-3Ј), to yield genotypes for both systems from a single PCR reaction. Primer ArtUp is used to genotype the Ala6Val system; BanI cuts the 'C' (Ala, or common) allele. Primer R2-D2 is used to genotype the Asn40Asp system; DpnII cuts the 'G' allele (Asp, or rare) allele.
Digestion results in 26-bp and 128-bp fragments for ArtUp (5Ј end) or 25-bp and 129-bp fragments for R2-D2 (3Ј end), when the respective recognition sequences are present. Fragments were resolved by MetaPhor (FMC, Rockland, ME, USA) agarose gel electrophoresis. Berrettini et al 13 used similar primer placement; some PCR reactions included one of the primers described above together with the opposing primer described by them, 13 for genotyping a single system. For subjects heterozygous at both systems, molecular haplotyping was accomplished by sequentially digesting in BanI, then DpnII. If the less common alleles are on the same chromosome (haplotype Ala 6 Asn 40 -Val 6 Asp 40 ), one restriction site would be recognized on each chromosome, and predicted fragment sizes would then be 129, 128, 26 and 25 bp. If they are on opposite chromosomes (haplotype Ala 6 Asp 40 -Val 6 Asn 40 ), the former chromosome would contain two restrictions sites and the latter none, so predicted fragment sizes would then be 154, 103, 26, and 25.
Data analysis
Deviation from the genotype counts predicted by Hardy-Weinberg (HW) equilibrium expectations was tested using an exact test, as described by Weir 23 and implemented in software written by Lewis and Zaykin 24 (Genetic Data Analysis (GDA) version 1). Variation in allele frequencies among control populations was tested by 2 × 7 2 contingency table analysis. We used the CLUMP program 25 to estimate empirical significance values of the 2 statistic (T1) using 10 000 Monte Carlo simulations. Comparisons between sets of two populations used the Fisher exact test (FET).
Hierarchical logistic regression was used to examine the association of race, sex and OPRM1 genotypes with diagnosis (substance-dependent vs control). The following independent variables were entered in the order shown: race, sex, Ala6Val genotype, Asn40Asp genotype and all two and three-way interactions involving these variables. The three-level race variable was entered using two orthogonal contrasts (EA vs AA or Hispanic, and AA vs Hispanic). Because of the absence of homozygotes for the rare allele, the Ala6Val genotype was dichotomized (ie, presence/absence of the rare allele). The Asn40Asp genotype was trichotomized (homozygous for the common or rare alleles and heterozygous). Since there is no a priori basis to determine the order of entry of genotypes in the regression equation, the analysis was repeated with the Asn40Asp genotype being entered first. Reversing the order of entry of the genotypes, however, yielded results that were comparable to those obtained using the order of independent variables described above.
The use of hierarchical regression made it possible to control for the effects of race and sex prior to examining the effect of the two genotypes on diagnosis (controls vs alcohol-or drug-dependent subjects). This approach also made it possible to examine the contribution to diagnosis of all two-way and three-way interactions involving these variables. To maximize the degrees of freedom available and the parsimony of the model, all variables that were nonsignificant and accounted for less than 1% of the variance were removed from the analysis using a backward elimination approach.
Subsequent to the analysis in which all 519 subjects were included, similar analyses were conducted to examine predictors of specific substance use diagnoses. In these three secondary analyses, only control subjects and those with a specific substance use diagnosis (eg, alcohol dependence) were included.
We also studied linkage disequilibrium (LD) between three polymorphisms at this locus (Ala6Val, Asn40Asp, and the STR) in a sample of 96 AA subjects and 274 EA subjects ('LD sample'); the LD sample was composed of drug-dependent, alcohol-dependent, and control subjects, and overlapped considerably but not completely with that used for the clinical analyses. LD was evaluated using an exact test as implemented in GDA version 1.0 software; probability levels reflect estimates of significance based on a shuffling test.
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Results
There were no deviations from HW expectations in any populations (control, substance-dependent, or alcohol-dependent).
Allele frequencies and sample sizes are presented in Table 1 . There was significant heterogeneity among the set of control populations for each polymorphism; for Ala6Val, 2 = 48.7; P Ͻ 0.0001; for Asn40Asp, 2 = 69.3; P Ͻ 0.0001 (Figure 1) .
Specific allele frequency comparisons between EA and AA control populations showed significant differences in allele frequency for both systems. For Ala6Val, P Ͻ 10 , for Asn40Asp, P Ͻ 0.001 (FET). Within-population comparisons of allele frequency by diagnosis showed no significant differences. For AA subjects, control vs SD groups, Asn40Asp, P = 0.08; Ala6Val, P = 0.28. For EA subjects, control vs SD groups, Asn40Asp, P = 0.32; Ala6Val, P = 0.30. For EA subjects, control vs alcohol dependence groups, Asn40Asp, P = 0.27; Ala6Val, P = 0.57. For Hispanic subjects, control vs SD groups, Asn40Asp, P = 0.42; Ala6Val, P = 0.61 (all FET) (Figure 2) . Thus, we found, in summary: (1) large differences in allele frequency for both systems by population (note, eg, the Asn40Asp frequency in the Japanese compared to all other populations; Table 1 ); (2) no significant differences, within population, by diagnosis.
We used regression analysis to further evaluate possible relationships between genotype and substance (drug or alcohol) dependence. Race was a significant predictor of diagnosis [ 2 (2) = 6.54, P = 0.038; Wald (2) = 11.26, P = 0.004]; this simply reflects the relative sizes of the SD and control groups, which differ by population. Of the orthogonal contrasts involving race, only that comparing EAs with AAs and Hispanics was significant [Wald (1) = 6.45, P = 0.011]. This reflected the fact that 80.6% of EA subjects were substancedependent compared with 70.3% of AAs and Hispanics Of the interactions, only that involving race × sex was significant [ 2 (2) = 11.18, P = 0.004; Wald (2) = 9.13, P = 0.010]. The first orthogonal contrast (EAs vs AAs and Hispanics) did not interact significantly with sex [Wald (1) = 0.003, P = 0.96]. However, the second contrast (AAs vs Hispanics) was significant [Wald (1) = 7.88, P = 0.005], which reflected the fact that among AAs a greater percentage of substancedependent subjects were males (65.8%) compared with Hispanics (42.9%). Conversely, among AAs, the percentage of control subjects who were male (44.1%) was smaller than that among Hispanics (80.0%).
The three secondary regression analyses (ie, focusing on specific diagnoses of alcohol, cocaine, or opioid dependence) yielded results that were generally comparable to the overall analysis. That is, in no case did either polymorphism (either as a main or interaction effect) account for unique variance in diagnosis. Allele frequencies for both polymorphisms by specific diagnosis are given in Table 2 . Some subjects received more than one specific diagnosis and were counted for the purposes of this tabulation in more than one category (which was not the case for Table 1) .
Haplotype results We observed a total of four subjects heterozygous at both systems: an AA cocaine-dependent subject, an AA alcohol-dependent subject, an Ethiopian, and a Bedouin. (The AA alcohol-dependent subject is not discussed elsewhere or included in the analyses because of insufficient numbers in that diagnostic group for AAs.) All these subjects had the Ala 6 Asp 40 -Val 6 Asn 40 genotype, ie the rarer alleles were on opposite chromosomes (example, Figure 3 ). All other haplotypes could be resolved unambiguously because all other subjects were homozygous for at least one of the systems; the Val 6 Asp 40 haplotype was never observed.
Linkage disequilibrium analysis For each population, all four possible LD relationships were evaluated, ie, each pairwise set of markers and the three markers taken together. In the AA sample, there was a trend for LD between Ala6Val and the STR (P = 0.08) and there was significant LD across all three systems taken together (P = 0.04). The other LD measures did not Table 2 Allele frequencies for substance-dependent subjects by specific substance of abuse. Some subjects were dependent on more than one substance and are included in more than one diagnostic group. Only subjects genotyped for both systems are included
Alcohol-dependent
Cocaine reach significance. In the EA sample, there was significant LD between Asn40Asp and the STR (P = 0.04) and a trend for LD across the three systems taken together (P = 0.07). The other LD measures did not reach significance.
Discussion
The rapid genotyping method presented here will facilitate future studies of this important gene. The present data document a large range in allele frequency (from a low of 0.047 in the AAs to a high of 0.485 in the Japanese) for the functional Asn40Asp polymorphisms in the seven populations studied, and a more narrow range (from a low of 0 in the Japanese and Hispanics to a high of 0.123 in the AAs) for the Ala6Val polymorphism. For both polymorphisms, there is significant heterogeneity between populations, and for both there are, specifically, significant differences between African and European Americans. The observation that in six of the seven populations studied either one variant or the other, but not both, has frequency Ͼ5%, coupled with the molecular haplotype data showing that the two less common alleles never occur on the same chromosome in this sample, suggest that the Ala 6 Asn 40 chromosome represents the ancestral haplotype. (The exception is the Ethiopian sample, where allele frequencies were 0.082 (Val6) and 0.173 (Asp40), respectively.) The existence of important population variation for both of these polymorphic sites is consistent with our previously reported population data for another polymorphism at this locus. 17 For that short tandem repeat (STR) polymorphism, there was not, however, a significant difference in allele frequency between African and European Americans. There was no significant difference for allele frequency for either system in our Hispanic subjects by phenotype; that is, we could not confirm the results of Bond et al. 15 We observed an allele frequency in affected subjects identical to what they observed in their affected subjects, but our controls showed a lower allele frequency than theirs. We speculate that the difference in allele frequency for Hispanic controls (0.14 vs 0.39) may be attributable to the very small sample size (only nine subjects) available to Bond et al. 15 However, our sample size is also very small (36 chromosomes, or 18 subjects) and other explanations are possible. Nonetheless, if the hypothesis is accepted that the difference in allele frequency shown by Bond et al 15 is attributable to functional variation in the protein, it is then difficult to explain why this was observed initially only in Hispanic subjects. Parsimony suggests that this is unlikely, taking into account the observed association only in a group with a very small sample; moreover, this group represents the most admixed and heterogeneous population studied (membership defined by language rather than geographical region of origin or any physical features). It is also possible that these observations reflect a minor effect of this variant, and with a sufficiently large sample, such an effect would be observed in other populations. For each of the three populations we studied, the frequency of the Asp40 variant was nonsignificantly higher in control samples, which could be viewed as consistent with the Bond et al 15 suggestion of a protective effect for this allele with respect to phenotype.
Power analysis suggested that a sample size of 40 subjects (divided equally between affected and unaffected) would have been sufficient to replicate the finding of Bond et al, 15 and 162 subjects (also divided equally between ill and well) to replicate the finding of Berrettini et al, 13 both for ␣ = 0.05 and ␤ = 0.20 (80% power). Since the Berrettini et al finding was not reported as population sensitive, we clearly had sufficient power to replicate this finding. The Bond et al result was, however, confined to Hispanic subjects; on that basis the present study had limited, but probably adequate, power to replicate (as our 46 Hispanic subjects were not divided evenly by diagnosis).
Although there were between-population differences in allele frequency for both polymorphisms, there was no significant within-population difference by diagnosis. Furthermore, after controlling for population differences, no significant effect of genotype on diagnosis was observed, despite a sample size in excess of 500 subjects. Similarly, when the sample was subdivided based on the presence of a specific substance use diagnosis, no effect of genotype was observed. Parsing out the results for drug dependence separately by specific drugs of abuse for inspection of allele frequencies (Table 2) , did not provide any consistent patterns suggestive of association with opioid rather than cocaine dependence, or vice versa. Of the previous reports of exon 1 polymorphism at this locus, our results are most consistent with those of Bergen et al 14 who reported no linkage or association with substance dependence. We could not replicate the positive findings of Berrettini et al, 13 regarding an increased frequency of the 6Val variant in American substancedependent subjects, or of Bond et al, 15 who found a decreased frequency of the 40Asp variant in American Hispanic substance-dependent subjects. Our results differed from those of Berrettini et al, 13 in several respects: (1) although they did not identify differences in Ala6Val frequency between EA and AA subjects, in our sample the difference was highly significant; P Ͻ 10 −6 (FET); (2) we did not identify significant differences in allele frequency in either EAs or AAs by phenotype. Although Berrettini et al 13 identified only the Ala6Val polymorphism in exon 1, their SSCP amplicon may also have contained the Asn40Asp site. If their assay actually detected both polymorphisms, this methodological difference could explain the difference in results.
In a previous study of an STR polymorphism at the OPRM1 locus, Kranzler et al 16 reported an association between OPRM1 alleles and substance dependence (including alcohol and drug dependence) that reached nominal, but not Bonferroni-corrected, significance. The results reported here suggest that if there really is an association, it must be explained by a polymorphism or polymorphisms other than the exon 1 variants studied here. A mutational analysis of most of the gene has been reported by Bergen et al, 14 but some regions not yet studied (9% of the coding region, plus much of the promoter) could harbor such variants.
In the EA sample, there was significant LD between the exon 1 polymorphism more common in that population, Asn40Asp, and the STR, and in the smaller AA sample, there was a trend for LD between the exon 1 polymorphism more common in that population, Ala6-Val, and the STR, and significant LD across the three markers. Thus, there is significant LD involving the STR and the other markers in each population. However, our LD analysis showed no significant LD between the two exon 1 polymorphisms in either population studied. The most likely explanation for this is lack of informativeness, because one of the polymorphisms was rare in each population, and the molecular haplotype analysis showed that the rare alleles were never observed on the same chromosome in our sample. In this situation, a very large sample is required to demonstrate significant LD. Given the LD shown with exon 1 markers, since the STR is much more informative in both populations than either exon 1 marker (with observed heterozygosity of 0.76 in AAs and 0.63 in EAs, compared to observed heterozygosities of 0.27 and lower for the other polymorphisms-observed in the LD sample), this STR represents a useful marker for other (as yet undescribed) polymorphic variation at this locus that could be responsible for phenotypic variation. The results of Bond et al 15 demonstrate that functional variation is tolerated at this locus. As such, LD with another polymorphism could provide an explanation for our previous positive results with this STR 16 in the presence of the negative results presented here.
Understanding genetic overlap between alcohol and drug dependence, and different forms of drug dependence, is very important for studies addressing the determination of the molecular genetic basis of each. Several studies addressing this issue have been published recently, and their results have bolstered the view that the genetic factors leading to alcohol and drug dependence are largely (but not entirely) separate; moreover, both distinct and common genetic factors affect liability to abuse particular substances. [26] [27] [28] That is, it should be possible to identify genes that predispose to the range of substance dependence disorders, as well as genes that contribute to drug dependence (in the aggregate), alcohol dependence, and certain different substance dependence disorders, including opioid and cocaine dependence, individually.
We found that in the present sample, neither OPRM1 exon 1 coding region polymorphism influences risk for substance dependence. A study using a family-controlled design could yield more definitive results; use of a family-controlled design would be important for this locus, as documented by the results presented here showing significant differences in allele frequency by population. A study with a much larger sample size would also be of interest in testing for a small protective effect of the Asp40 allele with respect to substance dependence.
